Publications by authors named "Pooja Manroa"
Article Synopsis
- Hürthle cell carcinoma (HCC) shows significant DNA copy number alterations (CNA) predominantly of genome haploidization type, with a notable occurrence in Hürthle cell adenomas (HCA), while being absent in Hürthle cell hyperplastic nodules (HCHN).* -
- In a study analyzing FNA samples, 34% of nodules with CNA were found to be malignant, and the likelihood of cancer increased with the size of the nodules, especially in those with GH-type CNA.* -
- Overall, the presence of CNA, combined with other genetic mutations and nodule size, provides valuable insights for predicting malignancy in thyroid nodules.*
Article Synopsis
- Thyroid adenoma-associated gene fusions are linked to thyroid cancers, but details about their frequency and related clinical features are not fully understood.
- A study examined 30 thyroid nodules identified as positive for these fusions through molecular testing, revealing that most had uncertain diagnoses, with a small percentage being malignant.
- Surgical outcomes showed that a majority underwent surgery, with about a third diagnosed as malignant; follow-up data indicated that these malignancies typically did not exhibit aggressive behaviors.
Article Synopsis
- The objective of the study is to evaluate the effectiveness of molecular testing (MT) in managing fine-needle aspiration (FN) results, specifically to differentiate between benign and potentially aggressive thyroid cancers (TC). Historically, thyroidectomy has been recommended for definitive diagnosis, but the role of MT is under review.
- Data from 389 patients were analyzed, revealing that MT was performed in 89% of cases, leading to a higher likelihood of thyroidectomy and accurate identification of histologic malignancies when MT results were positive.
- The study concluded that MT significantly increased cancer detection rates, identified aggressive malignancies effectively, and enabled safe nonoperative surveillance for a majority of patients with negative results, suggesting its integration
Introduction: One of the key features of the Bethesda System for Reporting Thyroid Cytopathology is the risk of malignancy (ROM), which guides management for each diagnostic category. However, calculation of the ROM can be challenging for indeterminate diagnoses because only a portion of cases will be resected for cytologic-histologic correlation (CHC) analyses. In the present study, we used the probability of cancer information from ThyroSeq, version 3, reports to calculate the molecular-derived (MD) ROM for indeterminate categories.
View Article and Find Full Text PDFTo determine the efficacy and safety of a diabetic ketoacidosis (DKA)-Power Plan (PP) for guiding intravenous (IV) insulin infusions prior to anion gap (AG) closure and administering subcutaneous (SC) insulin ≥1 hour before discontinuing IV insulin. Retrospective chart review of patients with DKA before (pre-PP) (n = 60) and following (post-PP) (n = 60) implementation of a DKA-PP. Groups were compared for percentage of patients for whom IV insulin therapy was continued until AG closure, the percentage of patients receiving SC insulin ≥1 hour before discontinuation of IV insulin, and percentage of patients with rebound DKA during the index hospitalization.
View Article and Find Full Text PDFBackground: The benign call rate (BCR) is the percentage of cytomorphologically indeterminate cases with subsequent benign or negative molecular results. For rule-out tests, the BCR is an important parameter because these molecular "negative" cases may be managed similarly to those with a benign cytology diagnosis. Although earlier versions of ThyroSeq molecular tests were less effective in excluding malignancy, the extensively expanded v3 version with a high negative predictive value is considered to represent a rule-out test.
View Article and Find Full Text PDFSelf-monitoring of blood glucose is a critical element in diabetes management. Providers must determine if and when patients are to perform glucose self-monitoring, set blood glucose targets, and help patients to interpret the results. Patients have a variety of continually evolving meters, supplies, and technology from which to choose.
View Article and Find Full Text PDFArticle Synopsis
- Type 2 diabetes (T2D) is linked to faster cognitive decline and conditions like Alzheimer's, especially in patients with metabolic syndrome, which is less studied.
- A study involving 47 T2D adults showed significant cognitive impairments: 13% struggled with memory, 50% with attention, and 35% with executive functions.
- Longer diabetes duration and higher levels of very low density lipoprotein were associated with poorer cognitive performance, indicating high risks for cognitive issues in T2D patients with metabolic syndrome.
Our understanding of the pathogenesis of idiopathic thrombotic thrombocytopenic purpura (TTP) has increased, but remains incomplete, particularly with respect to cases of suspected TTP that are either unresponsive to therapeutic plasma exchange (TPE) or have normal ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type 1 motif 13) activity. A 53-year-old woman presented with severe anemia (hemoglobin 1.8 g/dL) and clinical and laboratory findings consistent with TTP in conjunction with acute cocaine use.
View Article and Find Full Text PDFObjective: Hypercalcemia in patients with acromegaly is rare and usually due to co-existent primary hyperparathyroidism. The etiology of hypercalcemia directly related to acromegaly is debated.
Methods: We present a case report of 1,25(OH)2D3-mediated hypercalcemia in a patient with acromegaly and discuss potential pathophysiological mechanisms contributing to the development of hypercalcemia late in the course of the disease.